Expanding Opportunities in Contract Research and Contract Manufacture of Biotherapeutics Biologics

Pharmaceutical and Government funded research has spurred the growth of a $15 billion CRO industry. With more than $400 billion in pharmaceutical global sales revenue in 2006, biologics continue to drive pharmaceutical growth.

Contract Research Organizations (CROs) chaperone the entire process and supplement a pharmaceutical company's multi-faceted requirements as they operate in a tightly regulated environment of humans with meaningful concerns of public health and safety. CROs perform the role of a conduit of "medicines to be delivered to humans" and the pharmaceutical pipeline that is being marketed and sold. They have begun to gain dramatic prominence as they become global and the intermixing of the data from diverse ethnic groups has spurred personalized medicine and a streamlining of regulatory affairs.

Another driving force in the CRO industry is the looming expiry of several patents on blockbusters drugs. During 2006, branded drugs with total sales exceeding $18 billion have lost patent protection and an additional $21 billion of branded drugs are expected to lose patent protection during 2007 These developments open an enormously lucrative field through production of biosimilars through the required sophisticated manufacturing facilities. Contract Manufacturing Organizations are anticipated as the workhorses that will continue to channel the required drugs into the market.

Report Overview

D&MD's Expanding Opportunities in Contract Research and Contract Manufacture of Biotherapeutics/ Biologics market analysis report is a comprehensive compilation of CROs, CMOs and their numerous secondary interconnections. This report traces the funding of the CRO network and highlights failure points along the chain of the biologic's production including the realization that pharmaceutical productivity decline is most imminent in Phase II failure rates. The existing literature and trends associated with the pharmaceutical industry are reviewed comprehensively, and subsequently developed to encompass the entire field.

Buy this report and receive:

* Succinct explanations highlighting the science and the steps involved in the Pharmaceutical drug discovery process with emphasis on the details of the processes and challenges as well as the numerous entry points for CRO related services

* More than 50 figures to illustrate key trends and forecasts in the CRO market and other associated secondary markets

* A thorough analysis of pharmaceutical productivity that reiterates the need to re-strategize drug discovery and development and how CRO-related industries are growing into segments by providing specialized services geared towards optimizing these niches

* Insight to the rise of generics, the demise of several important patents and the overall regulatory environment that has just begun to emerge

About the Author: Gautam Thor received his PhD in Neurobiology in 1983 from The Tata Institute of Fundamental Research, India. He is the author of numerous scientific and medical publications and, is internationally recognized for his expertise in Pharmaceutical industry and human diagnostics

November 2007 Pages 162 Format PDF
Price: $995.00 / GBP497.50